Novo’s CagriSema Combo Shows ~22% Weight Loss but Falls Short of Expectations
Takeaways Obesity remains a global health challenge, prompting the development of advanced medical treatments. Novo Nordisk’s CagriSema is a promising new weight-loss therapy combining semaglutide and cagrilintide. This dual-action treatment…